Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Outer-limits who wrote (249)	3/24/2001 6:54:12 PM
From: Scott H. Davis	Respond to of 395

Most unprofitable biotechs have been putrid. I'd really like to see the short activity over the last few weeks, also fund redemptions. Otherwise it makes no sense, as biotechs are not tied to economic cycles or interest rates. The onl companies that would be adversely effected are those with little cash, as this would be a nasty secondary climate. VICL has made significant clinical progress in the past 5 years, no bad news, lots of cash, and look at their chart & where they are vs 5 years ago. quote.yahoo.com Not a rational market. I stepped asside in Feb, as that was irrational too. Unfortunately I came back into the market in Dec. IMSCO Scott